Eli Lilly (LLY): FY25 Q2 earnings call, Aug 7, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Aug 7, 2025 earnings call (FY25 Q2). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
13 matches for “Impact”; 5 quoted, at least 25 words apart.
…demand. We believe this medicine has the potential to make a significant impact on human health, and we will now work with urgency to submit…
…line, earnings per share increased 61% to $6.31, including of a negative impact of $0.14 from acquired IPR&D charges. This compares to $3.92 in Q2…
…in the base period related to Mounjaro launches in new markets. This impact was largely offset by volume growth of Mounjaro and Verzenio this year.…
…the same. While it's still early, we have seen this decision negatively impact Zepbound prescriptions during July and expect it to be a headwind to…
…to update our estimate as the situation changes. We expect the 2025 impact of currently announced tariffs to be modest, and this has been factored…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-08-07:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-08-07:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP